← Back to headlines
Curis Initiates Clinical Trial for Emavusertib Combination in CLL
Curis has opened 11 new sites for its TakeAim CLL trial, which is evaluating the emavusertib combination therapy for chronic lymphocytic leukemia.
29 Jun, 10:37 — 29 Jun, 10:37
Sources
Showing 1 of 1 sources
